Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications.

ABSTRACT:

Background

Expanding therapeutic possibilities have improved disease-related prospects for breast cancer patients. Pathological analysis on a tumor biopsy is the current reference standard biomarker used to select for treatment with targeted anticancer drugs. This method has, however, several limitations, related to intra- and intertumoral as well as spatial heterogeneity in receptor expression as well as the need to perform invasive procedures that are not always technically feasible.

Main body

In this narrative review, we focus on the current role of molecular imaging with contemporary radiotracers for positron emission tomography (PET) in breast cancer. We provide an overview of diagnostic radiotracers that represent treatment targets, such as programmed death ligand 1, h

SUBMITTER: Altena R 

PROVIDER: S-EPMC10192501 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature